TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07612189: A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

Sponsor: NEOK Bio, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 155 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$6,848,688

Rescue Site Savings

+$4,523,904

Unlock Full NCT07612189 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07612189 Rescue Dossier →